Opinion|Videos|January 22, 2025
Long-Term Safety of Second-Line Therapies for PBC
Panelists discuss how long-term safety monitoring for second-line primary biliary cholangitis (PBC) therapies requires systematic assessment of liver function, lipid profiles, and potential drug-specific adverse effects while emerging 5-year safety data for seladelpar continues to demonstrate a favorable risk profile compared with other treatment options.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the potential risks of long-term therapy with seladelpar, elafibranor, and obeticholic acid, and how can clinicians monitor for and mitigate these risks?
- Discuss the 5-year safety data for seladelpar presented at AASLD 2024.
- Discuss the 5-year safety data for seladelpar presented at AASLD 2024.
Advertisement
Related to this article
BRUIN CLL-313 showed significantly longer progression-free survival vs bendamustine plus rituximab, bringing a noncovalent BTK inhibitor to first-line care.
A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
American Pharmacists Month kicked off on October 1, honoring more than 700,000 pharmacy professionals and 250 years of caring for America's communities.
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
A pharmacist-led collaborative drug therapy management program at NYC Health + Hospitals/Bellevue reported high patient satisfaction, and every surveyed patient said they felt respected and supported by their pharmacist.
A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.
Advertisement
Advertisement
Trending on Pharmacy Times
1
EloraTZP Delivers Up to 23.3% Weight Loss in Adults With Obesity and T2D
2
Why Lp(a) Testing Lagged Behind LDL Cholesterol Screening
3
What the 2025-2030 Dietary Guidelines Mean for Heart Health
4
Pharmacists Key to Lp(a) Counseling and Lipid Optimization
5